Unmet needs in uncomplicated urinary tract infection in the United States and Germany: a physician survey.
Antibiotics
Primary care
Secondary care
Survey
Uncomplicated urinary tract infection
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
03 May 2023
03 May 2023
Historique:
received:
19
08
2022
accepted:
30
03
2023
medline:
5
5
2023
pubmed:
4
5
2023
entrez:
3
5
2023
Statut:
epublish
Résumé
Uncomplicated urinary tract infections (uUTIs/acute cystitis) are among the most common infections in women worldwide. There are differences in uUTI treatment guidelines between countries and understanding the needs of physicians in diverse healthcare systems is important for developing new treatments. We performed a survey of physicians in the United States (US) and Germany to understand their perceptions of, and management approaches to uUTI. This was a cross-sectional online survey of physicians in the US and Germany who were actively treating patients with uUTI (≥ 10 patients/month). Physicians were recruited via a specialist panel and the survey was piloted with 2 physicians (1 US, 1 Germany) prior to study commencement. Data were analyzed with descriptive statistics. A total of 300 physicians were surveyed (n = 200 US, n = 100 Germany). Across countries and specialties, physicians estimated 16-43% of patients did not receive complete relief from initial therapy and 33-37% had recurrent infections. Urine culture and susceptibility testing was more common in the US and among urologists. The most commonly selected first-line therapy was trimethoprim-sulfamethoxazole in the US (76%) and fosfomycin in Germany (61%). Ciprofloxacin was the most selected following multiple treatment failures (51% US, 45% Germany). Overall, 35% of US and 45% of German physicians agreed with the statement "I feel there is a good selection of treatment options" and ≥ 50% felt that current treatments provided good symptom relief. More than 90% of physicians included symptom relief amongst their top 3 treatment goals. The overall impact of symptoms on patients' lives was rated "a great deal" by 51% of US and 38% of German physicians, increasing with each treatment failure. Most physicians (> 80%) agreed that antimicrobial resistance (AMR) is serious, but fewer (56% US, 46% Germany) had a high level of confidence in their knowledge of AMR. Treatment goals for uUTI were similar in the US and Germany, although with nuances to disease management approaches. Physicians recognized that treatment failures have a significant impact on patients' lives and that AMR is a serious problem, though many did not have confidence in their own knowledge of AMR.
Sections du résumé
BACKGROUND
BACKGROUND
Uncomplicated urinary tract infections (uUTIs/acute cystitis) are among the most common infections in women worldwide. There are differences in uUTI treatment guidelines between countries and understanding the needs of physicians in diverse healthcare systems is important for developing new treatments. We performed a survey of physicians in the United States (US) and Germany to understand their perceptions of, and management approaches to uUTI.
METHODS
METHODS
This was a cross-sectional online survey of physicians in the US and Germany who were actively treating patients with uUTI (≥ 10 patients/month). Physicians were recruited via a specialist panel and the survey was piloted with 2 physicians (1 US, 1 Germany) prior to study commencement. Data were analyzed with descriptive statistics.
RESULTS
RESULTS
A total of 300 physicians were surveyed (n = 200 US, n = 100 Germany). Across countries and specialties, physicians estimated 16-43% of patients did not receive complete relief from initial therapy and 33-37% had recurrent infections. Urine culture and susceptibility testing was more common in the US and among urologists. The most commonly selected first-line therapy was trimethoprim-sulfamethoxazole in the US (76%) and fosfomycin in Germany (61%). Ciprofloxacin was the most selected following multiple treatment failures (51% US, 45% Germany). Overall, 35% of US and 45% of German physicians agreed with the statement "I feel there is a good selection of treatment options" and ≥ 50% felt that current treatments provided good symptom relief. More than 90% of physicians included symptom relief amongst their top 3 treatment goals. The overall impact of symptoms on patients' lives was rated "a great deal" by 51% of US and 38% of German physicians, increasing with each treatment failure. Most physicians (> 80%) agreed that antimicrobial resistance (AMR) is serious, but fewer (56% US, 46% Germany) had a high level of confidence in their knowledge of AMR.
CONCLUSIONS
CONCLUSIONS
Treatment goals for uUTI were similar in the US and Germany, although with nuances to disease management approaches. Physicians recognized that treatment failures have a significant impact on patients' lives and that AMR is a serious problem, though many did not have confidence in their own knowledge of AMR.
Identifiants
pubmed: 37138215
doi: 10.1186/s12879-023-08207-x
pii: 10.1186/s12879-023-08207-x
pmc: PMC10158246
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
281Informations de copyright
© 2023. The Author(s).
Références
JAMA Netw Open. 2022 Aug 1;5(8):e2225730
pubmed: 35925603
Int J Clin Pract. 2007 Feb;61(2):303-8
pubmed: 17263717
Eur Urol. 2020 Nov;78(5):645-646
pubmed: 32616407
Br J Gen Pract. 2017 Dec;67(665):e830-e841
pubmed: 29158245
Clin Infect Dis. 2021 Dec 6;73(11):1992-1999
pubmed: 34143881
Ther Adv Urol. 2019 May 02;11:1756287219832172
pubmed: 31105774
Urol Int. 2018;100(3):271-278
pubmed: 29539622
Nat Rev Urol. 2010 Dec;7(12):653-60
pubmed: 21139641
Fam Pract. 2005 Feb;22(1):71-7
pubmed: 15640290
Can Pharm J (Ott). 2021 Feb 16;154(2):100-109
pubmed: 33868521
Br J Gen Pract. 2020 Apr 30;70(694):e330-e338
pubmed: 32041765
Scand J Prim Health Care. 2013 Mar;31(1):50-5
pubmed: 23281925
J Urol. 2019 Aug;202(2):282-289
pubmed: 31042112
Clin Infect Dis. 2011 Mar 1;52(5):e103-20
pubmed: 21292654